• Infectex, of Moscow, said it received approval from the Russian Ministry of Health to begin a pivotal clinical trial for antibiotic SQ109 in multidrug-resistant tuberculosis (MDR-TB) patients at TB centers in three major Russian cities (Moscow, Saint Petersburg and Ekaterinburg).